Target intelligence / Profile preview

Catenin alpha-2 (CTNNA2)

Target
CTNNA2
Molecular classification
Other (Cell adhesion molecule; cytoskeletal adaptor protein)
01

Overview

Catenin alpha-2 (CTNNA2), also known as alpha-N-catenin, is a cytoplasmic protein predominantly expressed in the nervous system. It functions as a mechanosensing adaptor, linking cadherin-based cell adhesion complexes to the actin cytoskeleton, thus regulating cell-cell adhesion, neuronal migration, and neurite outgrowth. CTNNA2 is crucial for neural development, cortical neuronal migration, and synaptic remodeling. Loss-of-function mutations are associated with neurodevelopmental abnormalities and cortical dysplasia. Unlike some other catenin family members, CTNNA2 is not primarily recognized as a direct therapeutic target but is important for understanding cell adhesion and cytoskeletal regulation in health and disease[1][2][3][5]. Note: No approved drugs directly target Catenin alpha-2, and it is not currently classified as a major receptor, enzyme, transporter, or therapeutic target in clinical pharmacology[1][3].

Other names
Alpha-N-cateninCAP-RCT114catenin alpha 2cadherin-associated protein, relatedcancer/testis antigen 114CDCBM9catenin α 2CatnaCATNA2CDNRchpLOC107985902α N-cateninalpha-catenin-related protein
02

Biological functions

Cell-cell adhesionRegulation of actin cytoskeletonNeuron migration and neural developmentNegative regulation of Arp2/3 complex-mediated actin nucleationRegulation of neuron projection developmentMorphological plasticity of synapses
03

Disease associations

Neurodevelopmental disorders (e.g., complex cortical dysplasia)Cancer (not as a direct therapeutic target but as a potential biomarker or disease correlate)Hereditary breast ovarian cancer syndrome (association)

Beyond the preview

Go deeper on Catenin alpha-2 (CTNNA2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Catenin alpha-2 (CTNNA2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call